Clinical trials: Hepatic Cirrhosis
Hepatitis C
Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis
1. Achieve sustained virologic response (SVR) in patients infected with HCV genotype 1, cirrhosis, and early clinical decompensation using 12 weeks of Olysio/Sovaldi/Ribavirin (or known as…
- Trial name
- NCT02455167
- Testing
- Simeprivir (SMV), Sofosbuvir (SOF), Ribavirin (RBV)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Colorado, Denver
Chronic Hepatitis B
Improvement of Hard Endpoint in Chronic Hepatitis B Patients Treated With Antiviral Therapy
Patients who have completed 3 years follow-up of the past Beijing Science and Technology Commission Research will receive another 7-years anti-viral therapy.
- Trial name
- NCT03366571
- Testing
- Nucleos(t)ide Analogues
- Where
- 4 sites in China
- Volunteers
- 600 people
- Sponsor
- Beijing Friendship Hospital
Chronic Hepatitis C, Chronic Hepatitis B
The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in China
Subjects can be classified into two groups, Group 1 include non-cirrhotic patients, Group 2 include cirrhotic patients. All the patients will be received prophylactically TAF for 4 weeks before using SOF/VEL once daily for 12…
- Trial name
- BDTAF (NCT04997564)
- Testing
- Tenofovir Alafenamide 25 MG, Sofosbuvir / Velpatasvir
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Peking University First Hospital
Liver Fibroses
Effect of Some Drugs on Liver Fibrosis
Effect of Some Drugs on Liver Fibrosis
- Trial name
- NCT03770936
- Testing
- Candesartan, Ramipril
- Where
- Egypt
- Volunteers
- 45 people
- Sponsor
- Sherief Abd-Elsalam
Microbiota, Hepatocellular Carcinoma
Probiotics in the Prevention of Hepatocellular Carcinoma in Cirrhosis
Background. The main risk factor for the development of hepatocellular carcinoma (HCC) is cirrhosis of any etiology, with an annual risk between 1 and 6%, being currently the leading cause of death in patients with cirrhosis and…
- Conditions
- Microbiota, Hepatocellular Carcinoma, Cirrhosis
- Trial name
- NCT03853928
- Testing
- Probiotics
- Volunteers
- 280 people
- Sponsor
- Austral University, Argentina
Cirrhosis
Thrombin Generation Test in Patient With Liver Cirrhosis
Cirrhotic patients are patients with high morbidity and mortality, it is very important for determining the prognosis of these patients. The importance increases when these patients waiting for a liver transplant.
- Trial name
- NCT02484534
- Where
- Israel
- Volunteers
- 36 people
- Sponsor
- HaEmek Medical Center, Israel
Metabolic Associated Fatty Liver Disease, Metabolic Associated Steatotic Liver Disease
Evaluation of Non-Invasive Tests for Metabolic Liver Disease
The Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effort to standardize, validate and advance the regulatory qualification of blood- and imaging-based biomarkers…
- Conditions
- Metabolic Associated Fatty Liver Disease, Metabolic Associated Steatotic Liver Disease, Cirrhosis, Liver, NASH
- Trial name
- NIMBLE (NCT07122700)
- Where
- 4 sites in United States
- Volunteers
- 400 people
- Sponsor
- Foundation for the National Institutes of Health
Chronic Liver Disease and Cirrhosis, Liver Transplant; Complications
Magnetic Resonance Cholangiopancreatography in Living Liver Donors and Its Relationship With Post Operative Recipient Biliary Complications
Living donor liver transplantation is widely accepted as an life-saving treatment for patients with end-stage liver diseases. Careful donor selection is essential to maximize the success and minimize the risk of postoperative…
- Conditions
- Chronic Liver Disease and Cirrhosis, Liver Transplant; Complications, Donor Hepatectomy
- Trial name
- NCT07715500
- Testing
- Magnetic Resonance Cholangiopancreatography
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Ascites, Variceal Bleeding
VIATORR® TIPS Study Evaluating 6-10mm Diameters (VIATIPS)
This Registry will look at patients being treated with a transjugular intrahepatic portosystemic shunt (TIPS) procedure for portal hypertension.
- Conditions
- Ascites, Variceal Bleeding, Portal Hypertension Related to Cirrhosis
- Trial name
- VIATIPS (NCT07390344)
- Testing
- GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion (6-10mm)
- Where
- 3 sites in United States
- Volunteers
- 152 people
- Sponsor
- W.L.Gore & Associates
Liver Cirrhosis(Who Will Undergo Planed Liver Transplantation)
The Comparison of Changes of QTc, Tp-e Interval, and Tp-e/QT Ratio, Tp-e/QTc Ratio on the ECG During Living Donor Liver Transplantation Under Desflurane and Total Intravenous Anesthesia -Randomized Controlled Trial
Prolonged corrected QT interval (QTc) has been observed in about half of patients with liver cirrhosis. Marked prolongation of QTc (ie, 500 msec) has been considered to be a risk factor for fatal ventricular arrhythmia, such as…
- Trial name
- NCT03864276
- Testing
- inhalation (desflurane) group, total intravenous (propofol) anesthesia
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Yonsei University
Cirrhosis, Ascites
Application of Bacterial DNA Quantitative Detection in Diagnosis of SBP in Cirrhosis: A Multi Center Diagnostic Experiment
Background and Significance: Spontaneous bacterial peritonitis (SBP) is a common and life-threatening complication in patients with liver cirrhosis, characterized by high incidence and mortality.
- Conditions
- Cirrhosis, Ascites, Bacterial Infections
- Trial name
- NCT06995846
- Testing
- Bacterial DNA Levels in Ascites
- Where
- China
- Volunteers
- 700 people
- Sponsor
- Beijing YouAn Hospital
Cirrhosis, Type 1 Hepatorenal Syndrome
Terlipressin Given As I.V. Boluses Versus Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome
It is well known that terlipressin and albumin improve renal function in patients with cirrhosis and type 1 HRS. In previous studies terlipressin has been used either as intravenous boluses moving from an initial dose of 0.5-1…
- Trial name
- NCT00742690
- Testing
- terlipressin given by intravenous boluses and albumin, terlipressin given by continuous intravenous infusion and albumin
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- University of Padova
Cirrhosis
Norfloxacin Therapy for Patients With Cirrhosis and Severe Liver Failure
Patients with advanced cirrhosis have abnormal translocation of Gram-negative bacteria across the intestinal barrier and subsequent systemic inflammatory response.
- Trial name
- NORFLOCIR (NCT01037959)
- Testing
- Norfloxacin
- Where
- France
- Volunteers
- 291 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Muscle Cramp, Liver Cirrhosis
A Study Evaluating the Efficacy and Safety of Pregabalin Against Frequent Muscle Cramp in Patients With Liver Cirrhosis
Muscle cramp is defined as a paroxysmal, involuntary, and painful contraction of skeletal muscle. Cirrhotic patients can encounter with muscle cramp frequently, which might be associated with poor quality of life.
- Trial name
- NCT01271660
- Testing
- Pregabalin
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Boramae Hospital
Liver Cirrhosis, Septic Shock
Terlipressin in Septic Shock in Cirrhosis
Septic shock is a frequent and severe complication in cirrhosis. Current mortality rate ranges between 50 and 80% of cases. Refractory shock, hepatorenal failure and variceal bleeding are the main causes of death of these…
- Trial name
- NCT00628160
- Testing
- Terlipressin, alpha adrenergic drugs
- Where
- Spain
- Volunteers
- 72 people
- Sponsor
- Hospital Clinic of Barcelona
Chronic Liver Disease (CLD), Liver Cirrhosis
Heart Problems in Children With Chronic Liver Disease
Chronic liver disease (CLD) in children can sometimes lead to complications in other parts of the body, including the heart. The primary purpose of this observational study is to assess the presence and type of cardiac problems…
- Conditions
- Chronic Liver Disease (CLD), Liver Cirrhosis, Cardiac Abnormalities, Portopulmonary Hypertension
- Trial name
- NCT07502196
- Volunteers
- 60 people
- Sponsor
- Assiut University
Cirrhosis, Hepatocellular Carcinoma
Comparison of Biannual Ultrasonography and Annual Unenhanced Magnetic Resonance Imaging for HCC Surveillance
The purpose of this study is to investigate clinical feasibility of annual non-contrast magnetic resonance imaging for surveillance of hepatocellular carcinoma in high-risk group, in comparison with biannual ultrasonography.
- Trial name
- NCT02854241
- Testing
- Biannual ultrasonography, Annual noncontrast liver MRI, Contrast enhanced liver CT
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Seoul National University Hospital
Liver Cirrhosis
Serosurvey of HAV Immunity and Single-dose Vaccine Immunogenicity Among Patients With Cirrhosis
Hepatitis A virus (HAV) superinfection in patients with cirrhosis can precipitate acute hepatic decompensation and significantly worsen outcomes.
- Trial name
- NCT07433881
- Where
- India
- Volunteers
- 360 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Liver Cirrhosis, Esophageal and Gastric Varices
The Effect of Carvedilol Vs Propranolol in Cirrhotic Patients With Variceal Bleeding
To compare the efficacy and safety of Carvedilol and Propranolol in patients with cirrhosis-related esophagogastric varices after multiple endoscopic treatments for secondary prophylaxis.
- Conditions
- Liver Cirrhosis, Esophageal and Gastric Varices, Hemorrhage
- Trial name
- NCT02385422
- Testing
- Carvedilol, Propranolol
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatic Encephalopathy, Urea Cycle Disorders
A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group
The purpose of this study is to determine the safety and tolerability of GT4P administered orally as a single dose, and twice daily for 7 consecutive days, to subjects with hepatic impairment with cirrhosis (Child-Pugh scores of…
- Trial name
- NCT00986895
- Testing
- HPN-100
- Where
- 2 sites in Ukraine
- Volunteers
- 32 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.